Navigation Links
Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Date:11/19/2007

- Study Results Determine Phase 2 Dosing Regimen -

SOUTH SAN FRANCISCO, Calif., Nov. 19 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced updated results from an ongoing Phase 1/2a open-label, dose escalation clinical trial of RAV12, its lead therapeutic antibody in development for the treatment of adenocarcinomas. The objectives of the study were to define the safety profile and maximum tolerated dose of RAV12, to define the pharmacokinetics and describe preliminary efficacy.

"The study results demonstrate that a fractionated dosing regimen allows us to deliver RAV12 with an acceptable level of toxicity, while maintaining exposure that is associated with a tumor response," said George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies. "We are particularly encouraged to have seen a clinical response in one of the patients with advanced stage gastrointestinal cancer. These findings further demonstrate the potential therapeutic value of RAV12."

Study Design

The phase 1 dose-escalation safety and pharmacokinetics (PK) trial was initiated in December 2004 in patients with recurrent adenocarcinoma who had received 1 to 3 prior treatment courses. RAV12 was administered initially four times weekly, then by fractionated dosing two or three times weekly. Thirty-three patients were treated in the dose escalation segment of the trial. Three cohorts were given a weekly dose of 0.3 mg/kg, 1.0 mg/kg, and 1.5 mg/kg, and three cohorts received fractionated dose schedules of 0.5 mg/kg twice weekly, 0.75 mg/kg twice weekly, and 0.5 mg/kg thrice weekly.

Patients all had confirmed adenocarcinoma of gastrointestinal origin or of other origin if they positively expressed the RAAG12 antigen. The majority of patients had colorectal, gastroesophageal, or pancreatic cancer. Patient responses were evaluated
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended March 31, 2015 on Thursday, May ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its first quarter 2015 ...
(Date:4/30/2015)... CUPERTINO, Calif., April 30, 2015  DURECT Corporation (Nasdaq: ... first quarter of 2015.  Total revenues were $4.8 million ... months ended March 31, 2015 as compared to total ... million for the three months ended March 31, 2014.At ... $29.8 million, compared to cash and investments of $34.9 ...
(Date:4/30/2015)... 2015 Pharmacists at Osco Drug have voted to ... Portland, Maine . The newly organized group consists of ... Shaw,s supermarkets throughout Maine . ... in securing them the powerful representation that Teamsters Local 340 ... President of Local 340. "We will work tirelessly, providing them ...
Breaking Medicine Technology:Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
... 02, 2007 /PRNewswire-FirstCall/ - YM,BioSciences Inc. ... develops,and commercializes differentiated products for patients ... randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) ... following orthopedic surgery.,AeroLEF(TM) met the primary ...
... 2, 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) ... clinical trial,of Fampridine-SR in people with multiple ... meeting. Andrew Goodman, M.D.,Director of the Multiple ... top-line results on walking ability, leg,strength, spasticity ...
Cached Medicine Technology:YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:5/1/2015)... The Workgroup for Electronic Data Interchange ... use of health IT to create efficiencies in healthcare ... the United States Government Accountability Office (GAO) for a ... Medicare. The report, “ Potential Uses of Electronically Readable ... the public on Apr. 24, 2015 and examines the ...
(Date:5/1/2015)... Hope For The Warriors® thanks All ... The Warriors® and military families. All American Ford presented ... The Warriors®, a national nonprofit dedicated to restoring a ... hope for our service members and our military families. ... collected and matched small autograph fee from fans and ...
(Date:5/1/2015)... 2015 The Quail Creek Relay for Life ... Since 2001, the Quail Creek Relay team has raised almost ... throughout the year, including their biggest event, January’s Dinner and ... , Quail Creek Relay for Life team was established ... Kerwin, fitness director, states, “I was hooked when I learned ...
(Date:5/1/2015)... May 01, 2015 Digital technology and ... pregnant women between prenatal appointments, a preliminary study ... a small sample of low-risk pregnant women, will be ... Washington University Medical Faculty Associates at the 2015 American ... Scientific Meeting, May 2-6. The digital technology used was ...
(Date:5/1/2015)... Veteran Outreach Pittsburgh - Events , The ... VA Vet Centers on May 6, starting at 5 p.m., ... in front of the SouthSide Works Theater, 425 Cinema Drive, ... the documentary, “That Which I Love Destroys Me,” and a ... Please contact Robert Novotney for more information on the VA ...
Breaking Medicine News(10 mins):Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 3
... Innovations, (Pink Sheets: SCLL) ACTIVTox(R) human liver toxicity tests ... standardized human liver cell line to identify potential toxicities ... is available now and can be used to help ... of our ACTIVTox testing system could help prevent recalls ...
... 21 Celator Pharmaceuticals today announced that it ... Inc. (Nasdaq: CEPH ). The ... application of Celator,s proprietary technology to an ongoing ... agreement provides an opportunity to leverage the technology ...
... MDdatacor, Inc ., a leader in health care ... today announced new functionality to support in tracking ... Care Program. The program is a collaboration between Wellmark ... to promote improved quality care and increased efficiency. ...
... Optimize Resources With Imaging, Behavioral and Chronic Management ... is now easier for providers and payors, thanks ... new Milliman Care Guidelines (R) 13th Edition. ... measures within the Care Guidelines, workflow ...
... are out the schoolroom door and off to the ... preventive steps to help protect their hearts.Prevention may be ... exercise, stay away from cigarettes and have check-ups.Be aware ... disorder known as Long QT Syndrome, research shows that ...
... Employer Interest in Their NicheDENVER, May 21 The ... their employees on international business trips to "get proactive" ... the state,s largest travel health provider."We are hearing from ... Reesman, president of Passport Health Colorado. "I think now ...
Cached Medicine News:Health News:FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing 2Health News:FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing 3Health News:Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc. 2Health News:Wellmark Leverages MDdatacor Technology to Streamline Immunization Tracking 2Health News:Wellmark Leverages MDdatacor Technology to Streamline Immunization Tracking 3Health News:Milliman Care Guidelines(R) Products Drive Efficiency Through Expanded Quality Tools 2Health News:Milliman Care Guidelines(R) Products Drive Efficiency Through Expanded Quality Tools 3Health News:Protect Your Kids' Hearts: Summer Activity Can Trigger Genetic Disorder, Say Results for Life, Sudden Cardiac Arrest Association 2Health News:Protect Your Kids' Hearts: Summer Activity Can Trigger Genetic Disorder, Say Results for Life, Sudden Cardiac Arrest Association 3Health News:H1N1 Scare Causes Businesses to Get Serious About Travel Health 2
... an easy-to-use, automated system that enables you ... for managing hemostatic disordersincluding D-Dimer, Von Willebrand ... reflex and rerun testing for greater efficiency ... our high-quality service to help your lab ...
... RX ACCUNET Embolic Protection System is designed ... filter control when performing carotid stenting interventions. ... based filter system that utilizes rapid exchange ... control the filter during catheter manipulations. It ...
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
Medicine Products: